AbbVie (ABBV) Financial Analysis & Valuation | Quarter Chart

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor f... more
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The compa... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$453.84BExchangeNYSE
SectorHealthcareIndustryDrug Manufacturers - General
CountryUSCEORobert A. Michael
IPO Date2013-01-02CAGR9.55%
Employees57,000Websitewww.abbvie.com
Div. Yield2.69%Payout Ratio325%
Buy Back Yield0.33%Total Yield3.02%
ABBV chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
Enterprise Value$450.75BP/E Ratio25.21
Forward P/E15.78PEG Ratio-2.7
P/S Ratio7.14P/B Ratio16.4
P/CF Ratio21.25P/FCF Ratio21.53
EPS$10.19EPS Growth 1Y-13.29%
EPS Growth 3Y-52.02%EPS Growth 5Y-28.23%
Revenue Growth 1Y9.5%Gross Margin0.71%
Operating Margin0.28%Profit Margin0.06%
ROE0.68%ROA0.03%
ROCE0.18%Current Ratio0.8
Quick Ratio0.68Cash Ratio0.22
Debt/Equity2.65Interest Coverage5.96
Altman Z Score2.9Piotroski Score7

AbbVie (ABBV) valuation & financials

AbbVie (ABBV) has a market capitalization of $453.84B and trades at a price-to-earnings ratio of 25.2. It operates in the Healthcare sector (Drug Manufacturers - General).

AbbVie's revenue grew +9.5% over the last year.

AbbVie's next earnings report is scheduled for July 31, 2026 before market open; analysts estimate EPS of $3.76.

📈 Analysts estimate ABBV EPS of $3.76 for the upcoming quarter. See AbbVie revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

AbbVie (ABBV) — frequently asked questions

When does AbbVie (ABBV) report earnings next?

AbbVie is expected to report earnings on July 31, 2026 before market open. Analysts estimate EPS of $3.76.

What is AbbVie's market cap?

AbbVie (ABBV) has a market capitalization of $453.84B.

What is ABBV's P/E ratio?

AbbVie trades at a price-to-earnings ratio of 25.2, with trailing twelve-month EPS of $10.19.

How fast is AbbVie growing?

AbbVie's revenue grew +9.5% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW) · Novartis (NVS)